Dana-Farber Cancer Institute

A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.

Dana-Farber investigators presented encouraging positive results from the phase 2 ImmunoPRISM trial in smoldering myeloma.

The Yawkey Foundation made a $50 million grant to support Dana-Farber's planned cancer hospital and the Future of Cancer Care Fund.

Magnolia Contreras, MSW, MBA, of Dana-Farber Cancer Institute, was honored with The Lemuel Shattuck Award for Significant Contributions to Public Health Practice.

A small clinical trial led by Dana-Farber Cancer Institute builds on Salk Institute’s foundational research on vitamin D receptor and tumor microenvironment

Studies in pancreatic and prostate cancer selected for ASCO’s Plenary Program.

A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.

Researchers are optimistic about epigenetic tools for studying the impact of environmental exposures on genes, but further investigations are needed before drawing conclusions on the causes of early-onset colorectal cancer.

Dana-Farber Cancer Institute announced a gift to support cancer prevention and establish the Larry and Susan Marx Chair for Early Detection.

Toni Choueiri, MD, of Dana-Farber Cancer Institute, was elected to The Association of American Physicians.

Researchers used a genome-wide CRISPR knockout screen to pinpoint genes that help human AML cells avoid being engulfed by macrophages.

Kathleen Burns, MD, PhD, of has been elected as Fellow of the American Association for the Advancement of Science.

PANGEA-SMM outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment.

Tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis.

A detailed blueprint of tumor cell diversity could guide more precise, targeted treatments for supratentorial ependymomas.

Researchers at Dana-Farber Cancer Institute show why SCLC stays out of reach of the immune system, even when cancer cells are vulnerable to immune attack.

Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology, bringing together leading cancer researchers and clinicians.

Research showed that an oncolytic virus could prolong survival in patients with glioblastoma.

PATINA shows palbociclib added to anti-HER2 plus endocrine maintenance prolongs progression-free survival by 15+ months in HR+, HER2+ metastatic breast cancer.

Nicholas Polizzi, PhD, and Edward Boyden, PhD, are recipients of the December 2025 Medical Research Grant from the W. M. Keck Foundation.

A global analysis led by Dana-Farber combined patient data from 6 major clinical trials to compare 2 immunotherapies for advanced non–small cell lung cancer.

Extending endocrine therapy beyond 5e years significantly reduces relapse risk in young women with HR-positive early-stage breast cancer.

Investigators at Dana-Farber Cancer Institute have developed an AI-based noninvasive tool that can predict the likelihood of oropharyngeal cancer spread.

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program received exceptional ratings from the CIBMTR.

Dana-Farber Cancer Institute will present numerous presentations at ASH 2025 about studies in hematologic diseases and cancers.

Dana-Farber Cancer Institute was awarded a $20 million grant by The Elaine and Eduardo Saverin Foundation for advancements in metastatic breast cancer.

A study combined single-cell RNA sequencing data from patients with RCC to learn about patterns of interferon signaling across cell types in tumors.

The US FDA approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory AML with NPM1 gene mutations.

Osimertinib plus chemotherapy resulted in a significant and improvement in OS in newly diagnosed EGFR-mutated advanced NSCLC vs osimertinib alone.